“We remain laser-focused on executing on our development plans, and all ongoing trials remain on track as we progress IMVT-1402 through the clinic,” said Eric Venker, M.D., CEO of Immunovant (IMVT). Immunovant expects to report remission data from the batoclimab proof-of-concept study in GD at the American Thyroid Association Annual Meeting in September 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT: